Abstract:Polyglutamine (PolyQ) diseases include a group of inherited neurodegenerative disorders caused by unstable expansions of CAG trinucleotide repeats in the coding region of specific genes. Such genetic alterations produce abnormal proteins containing an unusually long PolyQ tract that renders them more prone to aggregate and cause toxicity. Although research in the field in the last years has contributed significantly to the knowledge of the biological mechanisms implicated in these diseases, effective treatments are still lacking. In this review, we revisit work performed in models of PolyQ diseases, namely the yeast Saccharomyces cerevisiae, the nematode worm Caenorhabditis elegans and the fruit fly Drosophila melanogaster, and provide a critical overview of the high-throughput unbiased genetic screens that have been performed using these systems to identify novel genetic modifiers of PolyQ diseases. These approaches have revealed a wide variety of cellular processes that modulate the toxicity and aggregation of mutant PolyQ proteins, reflecting the complexity of these disorders and demonstrating how challenging the development of therapeutic strategies can be. In addition to the unbiased large-scale genetic screenings in non-vertebrate models, complementary studies in mammalian systems, closer to humans, have contributed with novel genetic modifiers of PolyQ diseases, revealing neuronal function and inflammation as key disease modulators. A pathway enrichment analysis, using the human orthologues of genetic modifiers of PolyQ diseases clustered modifier genes into major themes translatable to the human disease context, such as protein folding and transport as well as transcription regulation. Innovative genetic strategies of genetic manipulation, together with significant advances in genomics and bioinformatics, are taking modifier genetic studies to more realistic disease contexts. The characterization of PolyQ disease modifier pathways is of extreme relevance to reveal novel therapeutic possibilities to delay disease onset and progression in patients.

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

Polyglutamine Protein Trafficking and Neurodegeneration

Nuclear Accumulation of Polyglutamine Disease Proteins and Neuropathology

Current Understanding on the Pathogenesis of Polyglutamine Diseases

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration

Polyglutamine Expansion Reduces the Association of TATA-binding Protein with DNA and Induces DNA Binding-Independent Neurotoxicity.

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

The Expanding Clinical Universe of Polyglutamine Disease.

Conformation Polymorphism of Polyglutamine Proteins

[Histone Deacetylase Inhibitors As Therapeutic Agents for Polyglutamine Disorders].

MicroRNAs and polyglutamine diseases]

Intracellular Degradation of Misfolded Proteins in Polyglutamine Neurodegenerative Diseases

Polyglutamine Expansion in Huntingtin and Mechanism of DNA Damage Repair Defects in Huntington's Disease

Polyglutamine Expansion of Huntingtin Impairs Its Nuclear Export

[The Advances in Research on Phosphorylation of Polyglutamine Disease].

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases

Context-dependent Dysregulation of Transcription by Mutant Huntingtin

Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets

Transcriptional dysregulation of TrkA associates with neurodegeneration in spinocerebellar ataxia type 17.